Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
OMCL 
Omnicell Inc (OMCL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/11/2025: OMCL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $44
1 Year Target Price $44
| 3 | Strong Buy |
| 1 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 27.53% | Avg. Invested days 41 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.53B USD | Price to earnings Ratio 66.56 | 1Y Target Price 44 |
Price to earnings Ratio 66.56 | 1Y Target Price 44 | ||
Volume (30-day avg) 8 | Beta 0.82 | 52 Weeks Range 22.66 - 55.74 | Updated Date 09/12/2025 |
52 Weeks Range 22.66 - 55.74 | Updated Date 09/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.5 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 2.01% | Operating Margin (TTM) 2.8% |
Management Effectiveness
Return on Assets (TTM) 0.49% | Return on Equity (TTM) 1.87% |
Valuation
Trailing PE 66.56 | Forward PE 29.5 | Enterprise Value 1501468873 | Price to Sales(TTM) 1.33 |
Enterprise Value 1501468873 | Price to Sales(TTM) 1.33 | ||
Enterprise Value to Revenue 1.31 | Enterprise Value to EBITDA 14.62 | Shares Outstanding 45934300 | Shares Floating 44819427 |
Shares Outstanding 45934300 | Shares Floating 44819427 | ||
Percent Insiders 1.79 | Percent Institutions 105.72 |
Upturn AI SWOT
Omnicell Inc
Company Overview
History and Background
Omnicell Inc. was founded in 1992. Initially focused on medication dispensing automation, it expanded through organic growth and acquisitions into a broader range of pharmacy and medication management solutions. Key milestones include IPO in 2001 and significant acquisitions to broaden product offerings.
Core Business Areas
- Medication Management Solutions: Automated dispensing systems, medication adherence packaging, and analytics to improve medication management in hospitals and pharmacies.
- Pharmacy Software Solutions: Cloud-based software solutions for pharmacy workflow automation, inventory management, and regulatory compliance.
- Central Pharmacy Automation: High-volume medication packaging and dispensing systems designed to streamline operations in central pharmacies.
Leadership and Structure
The company is led by Randall Lipps (Chairman, President, and CEO). The organizational structure includes functional departments such as sales, marketing, R&D, and operations, with regional sales teams.
Top Products and Market Share
Key Offerings
- XT Automated Medication Dispensing System: Automated medication dispensing cabinets used in hospitals and other healthcare facilities to improve medication safety and efficiency. Competitors include BD (Becton, Dickinson and Company), Capsa Healthcare, and Swisslog Healthcare. Market share is difficult to precisely quantify, but Omnicell is a leading player in this space.
- IVX Workflow: IV workflow software that automates the documentation and verification processes of IV compounding. Competitors include DoseEdge (Baxter), and Grifols. Market share is difficult to precisely quantify, but Omnicell is a leading player in this space.
Market Dynamics
Industry Overview
The medication management and pharmacy automation market is driven by increasing demand for improved medication safety, efficiency, and cost control in healthcare. Factors include an aging population, rising healthcare costs, and regulatory pressures.
Positioning
Omnicell is positioned as a leading provider of comprehensive medication management solutions, offering a broad portfolio of products and services for hospitals, pharmacies, and long-term care facilities. Competitive advantages include its extensive installed base, integrated solutions, and strong customer relationships.
Total Addressable Market (TAM)
The global pharmacy automation market is projected to reach USD 10.4 billion by 2028. Omnicell is well-positioned to capture a significant portion of this market due to its comprehensive product portfolio and strong market presence.
Upturn SWOT Analysis
Strengths
- Broad product portfolio
- Extensive installed base
- Strong customer relationships
- Integrated solutions
- Cloud-based solutions
Weaknesses
- High debt levels
- Dependence on healthcare spending
- Integration challenges with acquired companies
- Customer concentration
Opportunities
- Expanding into new markets
- Developing new products and services
- Acquiring complementary businesses
- Leveraging data analytics
- Cloud-based solution demand
Threats
- Increased competition
- Pricing pressure
- Regulatory changes
- Economic downturns
- Cybersecurity risks
Competitors and Market Share
Key Competitors
- BDX
- BMRN
- CAH
Competitive Landscape
Omnicell competes on product breadth, integration capabilities, and customer service. Competitors like BD (BDX) have a larger overall presence in the healthcare market, while others may specialize in specific areas of pharmacy automation.
Major Acquisitions
RxSafe, LLC
- Year: 2021
- Acquisition Price (USD millions): 275
- Strategic Rationale: Expanded Omnicell's portfolio to include more automation offerings for retail and specialty pharmacies.
Growth Trajectory and Initiatives
Historical Growth: Omnicell's historical growth has been driven by organic revenue growth and strategic acquisitions.
Future Projections: Future growth is expected to be driven by increased adoption of pharmacy automation and medication management solutions, as well as expansion into new markets.
Recent Initiatives: Recent initiatives include launching new cloud-based solutions and expanding its services offerings.
Summary
Omnicell is a key player in the medication management space, offering comprehensive solutions that drive efficiency and safety. High debt and integration challenges pose risks. Strong growth opportunities exist from expanding markets and cloud-based demand. It needs to continue innovation to stay ahead of competitors.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (10-K, 10-Q)
- Analyst reports
- Industry publications
- Press releases
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is based on estimates and may not be precise. Investment decisions should be based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Omnicell Inc
Exchange NASDAQ | Headquaters Fort Worth, TX, United States | ||
IPO Launch date 2001-08-07 | Founder, Executive Chairman, President & CEO Mr. Randall A. Lipps | ||
Sector Healthcare | Industry Health Information Services | Full time employees 3650 | Website https://www.omnicell.com |
Full time employees 3650 | Website https://www.omnicell.com | ||
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital; and specialized automated dispensing systems for hospitals, health systems, and post-acute care facilities. It also provides central pharmacy dispensing services; IV compounding services; turnkey solution designed to help health systems establish, manage, and optimize an entity-owned specialty pharmacy, as well as support onsite management of specialty pharmacy services, including payer contracting, staffing, licensing, and 340B program administration. In addition, the company offers inventory optimization services comprising predictive and prescriptive analytics, benchmarking, workflow tools, and clinical resources, as well as medication inventory visibility; patient engagement, clinical, and financial solutions; medication adherence solutions, which include single-dose automation solutions, automated and semi-automated filling equipment, various medication blister card packaging and packaging supplies; and software that guides users through the manual filling process. Further, it provides professional services, such as technology installation, program management, customer education and training, change management services, and related offerings; technical services comprising post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; and retail pharmacy and hospital automation outside the United States business. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. The company was incorporated in 1992 and is headquartered in Fort Worth, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.